22/12/2009ABLYNX DEMONSTRATES PROOF-OF-CONCEPT BY BIOMARKER FOR ITS ANTI-THROMBOTIC ALX-0081
14/12/2009ABLYNX INITIATES PHASE I FOR ALX-0141 (ANTI-RANKL)
02/12/2009ABLYNX WILL RECEIVE FURTHER MILESTONE PAYMENTS OF €3 MILLION AS PART OF ITS STRATEGIC ALLIANCE WITH BOEHRINGER INGELHEIM
26/11/2009ABLYNX WILL PRESENT AT PIPER JAFFRAY 21ST ANNUAL HEALTH CARE CONFERENCE IN NEW YORK
23/11/2009ABLYNX RECEIVES €1.1 MILLION GRANT TO FURTHER DEVELOP NEW ROUTES OF ADMINISTRATION FOR NANOBODIES®
18/11/2009ABLYNX ACHIEVES THIRD MILESTONE IN DRUG DISCOVERY AND DEVELOPMENT COLLABORATION
10/11/2009ABLYNX PROVIDES BUSINESS UPDATE FOR THE THIRD QUARTER 2009
30/10/2009ABLYNX ANNOUNCES WARRANT EXERCISE
23/10/2009ABLYNX WINS AWARD FOR 'MOST SUCCESSFUL EARLY PHASE TRIAL'
19/10/2009ABLYNX PROVIDES AN R&D UPDATE AND ANNOUNCES RECENT TECHNOLOGY ADVANCES
12/10/2009ABLYNX AND DOMANTIS SETTLE THEIR DISPUTE AND STOP THE ARBITRATION PROCESS
05/10/2009ABLYNX RECEIVES A SECOND MILESTONE PAYMENT FROM NANOBODY® DISCOVERY AND DEVELOPMENT ALLIANCE
01/10/2009ABLYNX RECEIVES MILESTONE PAYMENT AS PART OF ITS STRATEGIC ALLIANCE WITH BOEHRINGER INGELHEIM
30/09/2009WYETH PHARMACEUTICALS INITIATES PHASE II AND PAYS ABLYNX ANOTHER MILESTONE IN THE TNF-alpha NANOBODY® COLLABORATION
24/09/2009DISCLOSURE IN ACCORDANCE WITH THE TRANSPARENCY LEGISLATION OF 2 MAY 2007
15/09/2009ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE UBS GLOBAL LIFE SCIENCES CONFERENCE IN NEW YORK
01/09/2009ABLYNX INITIATES PHASE II CLINICAL TRIAL FOR ALX-0081
27/08/2009ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2009
24/08/2009ABLYNX WILL ANNOUNCE HALF-YEAR RESULTS FOR 2009 WITH WEBCAST
18/08/2009ABLYNX ANNOUNCES POSITIVE PHASE I RESULTS FOR SUBCUTANEOUS ADMINISTRATION OF ITS ANTI-THROMBOTIC NANOBODY® (ALX-0681)
28/07/2009ABLYNX ANNOUNCES WARRANT EXERCISE
02/07/2009ABLYNX PROMOTED TO THE BELGIAN MID-CAP INDEX
29/06/2009ABLYNX ANNOUNCES A NOVEL PRECLINICAL DEVELOPMENT CANDIDATE TARGETING IL6R
26/06/2009ABLYNX WINS EUROPEAN MEDISCIENCE AWARD FOR BEST TECHNOLOGY
25/05/2009Ablynx appoints Medical Director and Business Development Director
07/05/2009ABLYNX ANNOUNCES THAT ITS vWF NANOBODY® PROGRAMME HAS BEEN GRANTED ORPHAN DRUG DESIGNATION AND PROVIDES A BUSINESS UPDATE FOR THE FIRST QUARTER 2009
30/03/2009ABLYNX REPORTS DETAILED POSITIVE PHASE Ib RESULTS FOR ITS ANTI-THROMBOTIC NANOBODY® ALX-0081
24/02/2009ABLYNX ANNOUNCES 2008 FULL YEAR RESULTS
18/02/2009ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2008 WITH WEBCAST
05/02/2009ABLYNX ANNOUNCES SECOND EXTENSION OF ITS NANOBODY® DRUG DISCOVERY AND DEVELOPMENT ALLIANCE
03/02/2009ABLYNX RECEIVES €3 MILLION IN MILESTONE PAYMENTS AS PART OF ITS STRATEGIC ALLIANCE WITH BOEHRINGER INGELHEIM
20/01/2009ABLYNX EXPANDS ITS MUSCULOSKELETAL PORTFOLIO BY TAKING P&G PHARMACEUTICALS' PROGRAMME IN-HOUSE
14/01/2009ABLYNX ANNOUNCES TECHNICAL ADVANCES IN ITS NANOBODY® PLATFORM TECHNOLOGY: ENHANCED BENEFITS FROM PULMONARY DELIVERY AND HALF-LIFE EXTENSION
12/01/2009ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 27TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
08/01/2009ABLYNX STRENGTHENS MANAGEMENT TEAM WITH THE APPOINTMENT OF DR DEBBIE LAW AS CHIEF SCIENTIFIC OFFICER